Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel crystalline forms of gatifloxacin

Inactive Publication Date: 2005-12-29
NIDDAM HILDESHEIM VALERIE +3
View PDF3 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0055] In a further aspect, the present invention relates to methods of making hydrated E1, which method includes the step of treating gatifloxacin form E1-ACN solvate with a moist gas, especially moist gas of about 55% to about 75%-relative humidity at a temperature from ambient temperature to about 60° C., especially about 20° to 30° C.; although treating at 50° C. can be advantageous.

Problems solved by technology

However, it is generally not possible to predict whether a particular organic compound will form different crystalline forms, let alone predict the structure and properties of the crystalline forms themselves.
Absorption of atmospheric moisture by compound in powder form can impede its ability to flow.
The hemihydrate reportedly has disadvantages for manufacturing of solid oral dosage forms, e.g., tablets.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel crystalline forms of gatifloxacin
  • Novel crystalline forms of gatifloxacin
  • Novel crystalline forms of gatifloxacin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Form A

[0233] 3 g of gatifloxacin were slurried in 20 mL of iso-propanol (IPA). The mixture was slurried at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. The mixture was filtered under vacuum, rinsed with iso-propanol (IPA) (10 mL) and analyzed by XRD analysis and showed to be form A.

example 2

Form B

[0234] 3 g of gatifloxacin were slurried in 20 mL of 1-butanol. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with 1-butanol (10 mL), and analyzed by XRD analysis.

[0235] A second portion of the solid obtained after filtration was dried under vacuum at 50° C. for 24 hours. This resulted in a partially amorphous form B.

example 3

Form B

[0236] 3 g of gatifloxacin were slurried in 20 mL of EtOH absolute. The mixture was stirred at ambient temperature for a slurry time of 24 hours with a magnetic stirrer. Then the mixture was filtered under vacuum, the isolated solid rinsed with absolute EtOH (10 mL), and analyzed by XRD. The product was partially amorphous form B.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP.

Description

RELATED APPLICATIONS [0001] The present application claims the benefit of the filing date of the following U.S. Provisional Patent Applications: 60 / 379,510; 60 / 389,093; 60 / 401,672; 60 / 402,749; 60 / 409,860, 60 / 423,338; 60 / 432,961; 60 / 444,812; and 60 / 448,062.FIELD OF THE INVENTION [0002] The present invent relates to novel polymorphs and and pseudopolymorphs of (±) 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, commonly known as gatifloxacin. BACKGROUND OF THE INVENTION [0003] Gatifloxacin, known as (±) 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, has the following structure: [0004] Gatifloxacin, an anti-bacterial agent, is marketed as Tequin® by Bristol-Myers Squibb. Tequin® is available in a dosage of 200 and 400 mg in the form of a vial or a tablet, which can be either injected or taken orally. [0005] Many pharmaceutically active organic compounds can crystallize ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D215/56
CPCC07D215/56
Inventor NIDDAM-HILDESHEIM, VALERIEWIZEL, SHLOMITSTERIMBAUM, GRETAAMIR, EHUD
Owner NIDDAM HILDESHEIM VALERIE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com